CBS News

Genzyme's Mipomersen: Liver Side Effects Could Limit a Promising Cholesterol Drug

Genzyme's mipomersen, a promising new cholesterol drug, could offer new hope for patients who don't respond to existing lipid-lowering drugs such as statins. But there are also troubling questions ...
Monthly Prescribing Reference

Phase 3 trials of mipomersen for the treatment of hypercholesterolemia

Genzyme and Isis Pharmaceuticals announced results of two Phase 3 studies of patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. The first study was a ...
FierceBiotech

Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint

CAMBRIDGE, Mass. & CARLSBAD, Calif., Feb 10, 2010 (BUSINESS WIRE) -- Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that the phase 3 study of mipomersen in ...
Medscape

Mipomersen approved in US for homozygous FH

Bethesda, MD - The US FDA has approved mipomersen sodium (Kynamro, Genzyme, Cambridge MA), a once-weekly subcutaneous injection, as an adjunct to maximally tolerated lipid-lowering medications and ...
Healio

Mipomersen decreases atherogenic lipids, lipoproteins in patients with hypercholesterolemia

Please provide your email address to receive an email when new articles are posted on . Mipomersen significantly decreased levels of LDL cholesterol, apolipoprotein B and lipoprotein(a) in patients ...
Fierce Healthcare

Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patie

All patients in the study had the opportunity to self-administer mipomersen. Although the study was not designed to measure efficacy, the activity of mipomersen was clearly demonstrated and appeared ...
FierceBiotech

Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC

Study Meets Primary Endpoint with 28 Percent LDL-C Reduction CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE) -- Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced ...
Medscape

Mipomersen Lowers MACE in FH Patients, Analysis Shows

Led by Dr P Barton Duell (Oregon Health and Science University, Portland), the researchers analyzed data from three phase 3 randomized placebo-controlled trials of 104 patients with homozygous, ...
Medindia

How to Take Mipomersen Injection and it's Dose

Find out how to take Mipomersen Injection (drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.
Healio

Mipomersen sodium meets primary endpoint in FOCUS FH trial

Please provide your email address to receive an email when new articles are posted on . Isis Pharmaceuticals announced that mipomersen sodium, an oligonucleotide inhibitor of apolipoprotein B-100 ...
Forbes

FDA Review Raises Safety Concerns About Mipomersen

An FDA review raises a number of potentially significant safety concerns about the cholesterol-lowering drug mipomersen. The review appears ahead of a Thursday meeting of the Endocrinologic and ...